Advertisement
ALKS vs AMRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Hold and AMRX is a Hold.
ALKS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ALKS turned positive on October 05, 2026. Looking at past instances where ALKS's MACD turned positive, the stock continued to rise in 34 of 43 cases over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALKS's RSI Oscillator exited the oversold zone, 17 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on ALKS as a result. In 74 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
ALKS moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ALKS crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 74%.
Following a +2.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALKS advanced for three days, in 203 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 60 cases where ALKS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALKS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
ALKS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALKS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ALKS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 41 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.258) is normal, around the industry mean (7.271). ALKS has a moderately high P/E Ratio (114.750) as compared to the industry average of (0.479). ALKS's Projected Growth (PEG Ratio) (21.570) is very high in comparison to the industry average of (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (4.638) is also within normal values, averaging (181.047).
AMRX sees its Stochastic Oscillator recovers from oversold territory
On November 06, 2026, the Stochastic Oscillator for AMRX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 58 instances where the indicator left the oversold zone. In 49 of the 58 cases the stock moved higher in the following days. This puts the odds of a move higher at over 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +1.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRX advanced for three days, in 243 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMRX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 32 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRX as a result. In 56 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for AMRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 28 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
AMRX broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. AMRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMRX's P/B Ratio (212.412) is very high in comparison to the industry average of (7.271). P/E Ratio (40.280) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (1.947) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (1.899) is also within normal values, averaging (181.047).
ALKS | AMRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 41 | 6 | |
SMR RATING 1..100 | 85 | 99 | |
PRICE GROWTH RATING 1..100 | 40 | 37 | |
P/E GROWTH RATING 1..100 | 2 | 97 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALKS's Valuation (100) in the Biotechnology industry is in the same range as AMRX (100) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew similarly to AMRX’s over the last 12 months.
AMRX's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALKS (41) in the Biotechnology industry. This means that AMRX’s stock grew somewhat faster than ALKS’s over the last 12 months.
ALKS's SMR Rating (85) in the Biotechnology industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew similarly to AMRX’s over the last 12 months.
AMRX's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as ALKS (40) in the Biotechnology industry. This means that AMRX’s stock grew similarly to ALKS’s over the last 12 months.
ALKS's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for AMRX (97) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew significantly faster than AMRX’s over the last 12 months.
| ALKS | AMRX | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 77% | 4 days ago 71% |
| Stochastic ODDS (%) | 4 days ago 72% | 4 days ago 84% |
| Momentum ODDS (%) | 4 days ago 73% | 4 days ago 67% |
| MACD ODDS (%) | 6 days ago 79% | 4 days ago 64% |
| TrendWeek ODDS (%) | 4 days ago 72% | 4 days ago 66% |
| TrendMonth ODDS (%) | 4 days ago 73% | 4 days ago 83% |
| Advances ODDS (%) | 6 days ago 73% | 11 days ago 82% |
| Declines ODDS (%) | 8 days ago 65% | 5 days ago 68% |
| BollingerBands ODDS (%) | 4 days ago 62% | 4 days ago 71% |
| Aroon ODDS (%) | 4 days ago 59% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALKS’s FA Score shows that 1 FA rating(s) are green while AMRX’s FA Score has 1 green FA rating(s).
- ALKS’s FA Score: 1 green, 4 red.
- AMRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALKS’s TA Score shows that 6 TA indicator(s) are bullish while AMRX’s TA Score has 2 bullish TA indicator(s).
- ALKS’s TA Score: 6 bullish, 4 bearish.
- AMRX’s TA Score: 2 bullish, 5 bearish.
Price Growth
ALKS (@Pharmaceuticals: Generic) experienced а +1.24% price change this week, while AMRX (@Pharmaceuticals: Generic) price change was -6.37% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.13%. For the same industry, the average monthly price growth was -8.24%, and the average quarterly price growth was +8.66%.
Reported Earning Dates
ALKS is expected to report earnings on Feb 17, 2027.
AMRX is expected to report earnings on Feb 26, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (+2.13% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ALKS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with NBIX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then NBIX could also see price increases.
| Ticker / NAME | Correlation To ALKS | 1D Price Change % | ||
|---|---|---|---|---|
| ALKS | 100% | +3.05% | ||
| NBIX - ALKS | 34% Loosely correlated | +3.05% | ||
| VTRS - ALKS | 33% Poorly correlated | +4.96% | ||
| AMRX - ALKS | 30% Poorly correlated | +3.55% | ||
| ACET - ALKS | 30% Poorly correlated | +4.45% | ||
| LQDA - ALKS | 25% Poorly correlated | -0.20% | ||
More | ||||
AMRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with AMPH. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then AMPH could also see price increases.
| Ticker / NAME | Correlation To AMRX | 1D Price Change % | ||
|---|---|---|---|---|
| AMRX | 100% | +3.55% | ||
| AMPH - AMRX | 46% Loosely correlated | +3.00% | ||
| VTRS - AMRX | 43% Loosely correlated | +4.96% | ||
| TEVA - AMRX | 38% Loosely correlated | +1.99% | ||
| ANIP - AMRX | 38% Loosely correlated | -3.17% | ||
| COLL - AMRX | 33% Loosely correlated | -3.78% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HVAC | 27.50 | 0.68 | +2.54% |
| Advisorshares HVAC And Industrials ETF | |||
| BLCR | 46.91 | 0.51 | +1.10% |
| iShares Large Cap Core Active ETF (BLCR) | |||
| NML | 9.63 | 0.01 | +0.10% |
| Neuberger Energy Infrastructure and Income Fund Inc. | |||
| MYCJ | 24.15 | -0.02 | -0.10% |
| State Street My2030 Corporate Bond ETF (MYCJ) | |||
| TALV | 28.85 | -0.09 | -0.32% |
| Transamerica Large Value Active ETF | |||